There remains a need to better understand the incidence, impact, and management of brain metastases; mechanisms of resistance; optimal sequencing; and other patient- (e.g., smoking history) or disease-related factors (e.g., PD-L1 expression) that influence treatment outcomes of BRAF-mutant metastatic NSCLC. This evidence concerns the gene BRAF and non-small cell lung carcinoma.